Alizé Pharma 3 raises 67n mln euros
Alizé Pharma 3 said July 31 that it raised 67 million euros ($75 million) in a Series A round led by LSP. Novo Ventures, Kurma Partners, Orbimed, Pontifax, Partners Innovation Fund and Innobio 2 (managed by Bpifrance) participated in the round. Existing shareholders Sham Innovation Santé/Turenne Capital, Crédit Agricole Création and TAB Consulting also took part. Alizé Pharma 3, of France, develops therapeutic peptides for rare endocrine and metabolic diseases.
31 July 2019•7 mins read
